Dark

Check out our Level2View

CBAY
Cymabay Therapeutics
stock NASDAQ

Inactive

Mar 21, 2024

32.48USD+0.031%(+0.01)8,356,254

Pre-market

0.00USD-100.000%(-32.47)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 21, 2022

02:31PM EST Mid-Afternoon Market Update: Crude Oil Drops 2%; Limelight Networks Shares Spike Higher Benzinga

12:31PM EST Mid-Day Market Update: Dow Falls 100 Points; Netflix Shares Plummet Benzinga

10:14AM EST Mid-Morning Market Update: Markets Down; Schlumberger Earnings Top Views Benzinga

Nov 23, 2021

07:25AM EST CymaBay Therapeutics Granted U.S. Patent #11,179,359 'Treatment of NAFLD and NASH' Benzinga

Nov 18, 2021

08:19AM EST CymaBay Prices Offering Of 15.625M Shares At $4/Share Benzinga

08:00AM EST CymaBay Announces Pricing of Public Offering of Common Stock and GlobeNewswire Inc

07:55AM EST The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings Benzinga

Nov 17, 2021

04:34PM EST CymaBay Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants; No Terms Disclosed Benzinga

04:33PM EST CymaBay Announces Proposed Public Offering of Common Stock and GlobeNewswire Inc

Nov 15, 2021

11:09AM EST CymaBay Therapeutics Long-term Open Label Study Finds Treatment With Seladelpar For Two Years Improves Key Liver Biomarkers In Patients With PBC Benzinga

10:37AM EST The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More Benzinga

08:00AM EST CymaBay Therapeutics Long-term Open Label Study Finds Treatment GlobeNewswire Inc

Nov 11, 2021

09:23AM EST Raymond James Maintains Strong Buy on CymaBay Therapeutics, Raises Price Target to $14 Benzinga

08:00AM EST CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a Key Opinion Leader (KOL) webinar on seladelpar for primary biliary cholangitis (PBC) on Monday, November 15, at 4:30pm EST. GlobeNewswire Inc

Nov 10, 2021

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 4, 2021

08:00AM EDT CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc

Oct 1, 2021

08:00AM EDT CymaBay Therapeutics Announces Presentations at The Liver GlobeNewswire Inc

Aug 30, 2021

08:00AM EDT CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 12, 2021

04:47PM EDT CymaBay Therapeutics Q2 EPS $(0.34) Misses $(0.27) Estimate Benzinga

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

04:14AM EDT Earnings Scheduled For August 12, 2021 Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 3, 2021

06:25AM EDT HC Wainwright & Co. Maintains Buy on CymaBay Therapeutics, Lowers Price Target to $12 Benzinga

Aug 2, 2021

10:30AM EDT CymaBay Secures $100M Non-Dilutive Funding To Fund Seladelpar Development Program Benzinga

08:05AM EDT CymaBay Announces $100M Non-Dilutive Financing With Abingworth Benzinga

08:00AM EDT Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC GlobeNewswire Inc

Jun 21, 2021

08:05AM EDT CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress 2021 Benzinga

08:00AM EDT -- New analyses adds to the growing body of evidence for seladelpars potential as a treatment for patients with PBC GlobeNewswire Inc

Jun 14, 2021

10:47AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2021 Benzinga

09:00AM EDT JonesTrading Initiates Coverage On CymaBay Therapeutics with Buy Rating, Announces Price Target of $8 Benzinga

08:00AM EDT CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc

Jun 9, 2021

08:00AM EDT CymaBay Therapeutics Announces Presentations During The GlobeNewswire Inc

May 14, 2021

10:56AM EDT CymaBay Therapeutics shares were trading lower after the company reported worse-than-expected Q1 EPS Benzinga

May 13, 2021

04:44PM EDT CymaBay Therapeutics Q1 EPS $(0.25) Misses $(0.24) Estimate Benzinga

04:06PM EDT Highly experienced executives, Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer, strengthen the management team GlobeNewswire Inc

08:00AM EDT CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that medical and clinical leader Dennis D. Kim, MD, MBA, is joining the company as Chief Medical Officer. GlobeNewswire Inc

04:15AM EDT Earnings Scheduled For May 13, 2021 Benzinga

May 11, 2021

08:00AM EDT CymaBay Announces Inducement Grant Under Nasdaq Listing Rule GlobeNewswire Inc

May 10, 2021

08:00AM EDT Proven Leader in Building Commercial Organizations to Prepare Markets and Deliver Successful Product LaunchesPlanning for Seladelpar Launch as it Completes Development and Regulatory Submissions GlobeNewswire Inc

May 6, 2021

08:00AM EDT CymaBay Therapeutics to Report First Quarter 2021 Financial GlobeNewswire Inc

Apr 5, 2021

08:00AM EDT CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of GlobeNewswire Inc

Mar 25, 2021

04:18PM EDT CymaBay Therapeutics Q4 EPS $(0.23) Misses $(0.20) Estimate Benzinga

04:10PM EDT Actively recruiting patients in two global, clinical studies evaluating seladelpar in primary biliary cholangitis (PBC): GlobeNewswire Inc

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

04:03AM EDT Earnings Scheduled For March 25, 2021 Benzinga

Mar 12, 2021

08:00AM EST CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 GlobeNewswire Inc

Mar 11, 2021

08:00AM EST CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that two seladelpar presentations will be delivered during the NASH-TAG Conference being held March 11th 13th. GlobeNewswire Inc

Feb 24, 2021

08:00AM EST CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc

Feb 10, 2021

08:00AM EST CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Leerink 10th Annual Global Healthcare Conference taking place February 22-26, 2021. GlobeNewswire Inc

Nov 16, 2020

04:07PM EST CymaBay Therapeutics Announces Oral Late-Breaking Presentation Of Positive Results From The ENHANCE Global Phase 3 Study Evaluating Seladelpar For Primary Biliary Cholangitis At The Liver Meeting 2020 Benzinga

04:01PM EST -- Seladelpar demonstrated anti-cholestatic, anti-inflammatory, and anti-pruritic activity through 3 and 6 months -- Results highlight the potential for seladelpar to offer patients an efficacious and safe second line treatment option -- Global 52-week Phase 3 registration study (RESPONSE) to begin enrolling patients in Q1 of 2021 GlobeNewswire Inc

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 11, 2020

08:00AM EST CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 6, 2020

09:34AM EST Raymond James Maintains Strong Buy on CymaBay Therapeutics, Raises Price Target to $12 Benzinga

04:19AM EST SVB Leerink Maintains Outperform on CymaBay Therapeutics, Raises Price Target to $10 Benzinga

Nov 5, 2020

04:53PM EST CymaBay Therapeutics Q3 EPS $(0.17), Inline Benzinga

08:20AM EST CymaBay Announces Study To Evaluate The Potential For GPR119 Agonists To Prevent Hypoglycemia In Type 1 Diabetes Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

08:10AM EST CymaBay Therapeutics Announces Oral Late-Breaking Presentation Of Results From The ENHANCE Global Phase 3 Study Evaluating Seladelpar For Primary Biliary Cholangitis At The Liver Meeting 2020 Benzinga

08:00AM EST CymaBay Therapeutics Announces an Oral Late-Breaking Presentation GlobeNewswire Inc

Oct 30, 2020

04:32PM EDT CymaBay Therapeutics to Report Third Quarter 2020 Financial GlobeNewswire Inc

Oct 26, 2020

08:30AM EDT Stocks Trading Near 52-Week Highs Before Open On Monday, Oct. 26, 2020: SNAP, LLIT, DNKN, PINS, TWTR, PBI, CBAY, SI, ADM, BCOV, FIIIU Benzinga

Oct 20, 2020

08:17AM EDT The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger Benzinga

Oct 1, 2020

08:05AM EDT CymaBay Therapeutics To Present Data From Phase 2 Study Of Seladelpar In Patients With NASH At The Liver Meeting 2020 Nov. 13-16 Benzinga

08:00AM EDT CymaBay Therapeutics to Present Data from its Phase 2 Study of GlobeNewswire Inc

Sep 22, 2020

07:07AM EDT Milestone Pharma Appoints Lisa Giles And Robert Wills To Board, Effective October 1 RTTNews

07:01AM EDT Milestone Pharmaceuticals Appoints Lisa Giles And Robert Wills To Its Board RTTNews

07:01AM EDT Milestone Pharmaceuticals Strengthens Board of Directors with Two New PR Newswire

Sep 3, 2020

04:05PM EDT CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc

Sep 1, 2020

12:32PM EDT Avoro Capital Advisors Reports 14.95% Passive Stake In CymaBay Therapeutics Benzinga

Aug 27, 2020

08:01AM EDT CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study In Primary Biliary Cholangitis At The Digital International Liver Congress 2020 Benzinga

08:01AM EDT CymaBay Therapeutics Presents Positive Final Results From 52-Week GlobeNewswire Inc

Aug 25, 2020

07:55AM EDT Citi Raises CymaBay Therapeutics Price Target From $7 To $9 Benzinga

Aug 20, 2020

08:10AM EDT CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress 2020 Benzinga

08:00AM EDT CymaBay Therapeutics Announces Presentations During The Digital GlobeNewswire Inc

Aug 11, 2020

08:02AM EDT Raymond James Maintains Strong Buy on CymaBay Therapeutics, Raises Price Target to $11 Benzinga

Aug 10, 2020

04:12PM EDT CymaBay Therapeutics Q2 EPS $(0.16) Beats $(0.24) Estimate Benzinga

04:01PM EDT CymaBay Reports Second Quarter 2020 Financial Results and Provides GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 4, 2020

07:00AM EDT Cantor Fitzgerald Maintains Overweight on CymaBay Therapeutics, Raises Price Target to $20 Benzinga

06:23AM EDT HC Wainwright & Co. Maintains Buy on CymaBay Therapeutics, Raises Price Target to $13 Benzinga

Aug 3, 2020

04:01PM EDT CymaBay Therapeutics to Report Second Quarter 2020 Financial GlobeNewswire Inc

01:10PM EDT Watching CymaBay Therapeutics Shares; Hearing Cantor Sets Street-High Price Target Of $20 Benzinga

07:22AM EDT CymaBay Says Positive Topline Results From ENHANCE Study For Seladelpar In Patients With Primary Biliary Cholangitis RTTNews

07:07AM EDT CymaBay Calls Topline Results from its ENHANCE Study for Seladelpar in Patients with Primary Biliary Cholangitis 'Positive' Benzinga

07:00AM EDT CymaBay Announces Positive Topline Results from GlobeNewswire Inc

Jul 31, 2020

01:01PM EDT Piper Sandler Initiates Coverage On CymaBay Therapeutics with Overweight Rating, Announces Price Target of $12 Benzinga

Jul 23, 2020

01:26PM EDT CymaBay Therapeutics Shares Up 32% For The Session; Oppenheimer Raises Price Target From $6 To $10 Benzinga

10:35AM EDT Shares of CymaBay Therapeutics, Inc. (CBAY) are currently gaining over 35% on Thursday morning after the U.S. Food and Drug Administration lifted all clinical holds on the company's seladelpar. RTTNews

10:13AM EDT Mid-Morning Market Update: Markets Down; AT&T Earnings Beat Estimates Benzinga

09:20AM EDT CymaBay Therapeutics Inc. (CBAY) said that the U.S. Food and Drug Administration lifted clinical holds on seladelpar for all three Investigational New Drug (IND) Applications in Nonalcoholic Steatohepatitis or NASH, Primary Biliary Cholangitis or PBC and Primary Sclerosing Cholangitis or PSC. RTTNews

08:36AM EDT CymaBay Says Clinical Hold Lifted On Seladelpar INDs In NASH, PBC And PSC RTTNews

08:06AM EDT CymaBay Therapeutics Announces FDA Lifts All Clinical Holds On Seladelpar; Co. Re-initiating Clinical Development Focusing First On Phase 3 For PBC Benzinga

08:00AM EDT Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC GlobeNewswire Inc

Jul 14, 2020

04:21PM EDT Cymabay Therapeutics Says Entered Into Sales Agreement, With Cantor Fitzgerald, Relating To Shares Of Co's Common Stock; Under Terms, May Offer & Sell Shares Of Common Stock Having Price Of Up To $75M Through Cantor Fitzgerald Benzinga

Share